| OR | 95% CI | p |
---|---|---|---|
All patients-univariate | |||
 Age | 0.96 | 0.92–1.00 | 0.066+ |
 PSA ≥20 ng/mL | 1.26 | 0.66–2.41 | 0.480 |
 Clinical ≥T3 stage | 0.70 | 0.35–1.41 | 0.319 |
 GS ≥8 at biopsy | 1.29 | 0.69–2.42 | 0.430 |
 Treatment group RP | 4.61 | 2.36–9.00 | < 0.001* |
All patients-multivariate | |||
 PSA ≥20 ng/mL | 1.85 | 0.95–3.59 | 0.069+ |
 Treatment group RP | 5.35 | 2.69–10.61 | < 0.001* |
ExRT group-univariate | |||
 ADT use < 2-year | 1.98 | 0.72–5.49 | 0.188 |
 No PLI | 2.53 | 0.93–6.91 | 0.071+ |
ExRT group-multivariate | |||
 ADT use < 2-year | 2.42 | 0.85–6.89 | 0.098 |
 No PLI | 2.87 | 1.01–8.16 | 0.048* |
RP group-univariate | |||
 Positive surgical margin | 2.41 | 1.00–5.78 | 0.050* |
 Pathological N1 stage | 1.97 | 0.87–4.46 | 0.105 |
 Pathological ≥T3 stage | 2.17 | 0.65–7.32 | 0.210 |
 GS ≥8 at RP specimen | 1.83 | 0.80–4.18 | 0.154 |
RP group-multivariate | |||
 Positive surgical margin# | 2.41 | 1.00–5.78 | 0.050* |